par Biophytis (EPA:ALBPS)
Obesity: Biophytis Charts Its Course Toward a Booming Market
Paris, France, and Cambridge, Massachusetts – July 7, 2025 – Biophytis SA, a pioneering force in the development of transformative therapies for obesity, sarcopenia, and longevity, is seizing a major opportunity in the expanding obesity market by addressing an unmet medical need: preserving muscle mass and function in patients losing weight while treated with GLP-1 receptor agonists.
GLP-1 therapies such as semaglutide and tirzepatide have revolutionized obesity management by enabling significant weight loss. However, up to 40% of total weight lost can come from muscle tissue, raising concerns about long-term mobility, strength, and metabolic health. Biophytis is at the forefront of this challenge with its lead drug candidate, BIO101 (20-hydroxyecdysone), the first oral MAS receptor activator designed to counteract muscle wasting associated with GLP-1-induced weight loss.
Recent positive clinical results with enobosarm and bimagrumab—two agents targeting muscle preservation in obesity—further confirm the critical need for therapies that address muscle loss during weight reduction. These results not only expand the market potential for obesity treatments that preserve muscle mass but also pave the way for a clearer and more favorable regulatory pathway. Biophytis views these developments as a major opportunity, strengthening the relevance and timeliness of its OBA program with BIO101.
Market Potential and Strategic Positioning
With the global obesity market expected to reach $100 billion by 2030 and 96% of obese patients suffering from impaired muscle strength, Biophytis is uniquely positioned as the only company offering a solution focused on muscle quality and mobility restoration in this context. The growing recognition of this need by the pharmaceutical industry is reflected in recent large-scale acquisitions and partnerships within the sector.
Stanislas Veillet, CEO of Biophytis, commented: “We estimate that BIO101 has the potential to become the reference molecule for preserving muscle function in obese patients treated with GLP-1 receptor agonists. Our expertise in muscle diseases and the promising results already obtained in obesity will accelerate our clinical plan and position Biophytis as a key player in this rapidly growing market.”
***
About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company’s ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.
Disclaimer
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face" section from the Company’s 2023 Financial Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether because of new information or otherwise, except as required by law.
Biophytis Contacts
Investor Relations
US Investors
Pascal Nigen – Alpha Bronze
Media contacts
Antoine Denry: antoine.denry@taddeo.fr – +33 6 18 07 83 27
Inès de Mandiargues: ines.demandiargues@taddeo.fr - +33 6 16 16 51 78